The FDA granted orphan drug designation to an investigational drug for the treatment of Prader-Willi syndrome, according to an industry press release. Tesomet (Saniona) is an investigational, ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

Signaling pathways in the cerebellum, rather than the hypothalamus, could provide a key for developing new therapies for the genetic disorder. Disordered signaling in the cerebellum may help explain ...

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP ...

Soleno Therapeutics’ Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare ...